Bristol-Myers Squibb (BMS) has reported strong third quarter results, announcing an 11% increase in revenue to $5.35bn attributed to the company’s blood thinning drug Plavix.

Plavix turnover rose 8% to $1.79bn, while the company also reported increases to its portfolio of HIV drugs, with Sustiva and Reyataz climbing 5% and 4% respectively.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

BMS was, however, hit by a 29% fall in sales of Avapro/Avalide, used to treat hypertension.

CEO Lamberto Andreotti hailed the results and also praised data from the company’s trial of the stroke prevention medication Eliquis.

"We are excited by the strength of the Phase III data presented on Eliquis for stroke prevention in patients with atrial fibrillation and by the possibility that Eliquis could play a key role in the company’s future," he said.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact